Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 10:38 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Plaque Psoriasis Clear all
Terminated Phase 3 Interventional Results available

DFD01 Spray HPA Axis Suppression Study in Adolescent Patients With Moderate to Severe Plaque Psoriasis

NCT02527421
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
DFD01 Spray
Drug
Lead sponsor
Primus Pharmaceuticals
Industry
Eligibility
12 Years to 16 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
8
States / cities
Encino, California • Irvine, California • San Diego, California + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2024 · Synced Jul 21, 2026, 10:38 PM EDT
Not listed Not applicable Interventional

Efficacy and Safety Study of Autonomic Nerve Modulation (ANM) in Subjects With Moderate Plaque Psoriasis

NCT03817164
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
Autonomic Nerve Modulation - Active, Autonomic Nerve Modulation - Control
Device
Lead sponsor
Thync Global, Inc.
Industry
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Fremont, California
Source: ClinicalTrials.gov public record
Updated Jul 8, 2019 · Synced Jul 21, 2026, 10:38 PM EDT
Completed Phase 2 Interventional Results available

Comparison of Secukinumab Versus Guselkumab in Clearing Psoriatic Plaques Refractory to Ustekinumab

NCT03553823
View directory record Official record
Conditions
Chronic Plaque-type Psoriasis
Interventions
Skin biopsies
Procedure
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
4
States / cities
New Orleans, Louisiana • East Windsor, New Jersey • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2021 · Synced Jul 21, 2026, 10:38 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis

NCT03598790
View directory record Official record
Conditions
Chronic Plaque Psoriasis, Moderate to Severe Chronic Plaque Psoriasis
Interventions
Bimekizumab
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years and older
Enrollment
1,353 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
48
States / cities
Glendale, Arizona • Phoenix, Arizona • Bakersfield, California + 43 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Jul 21, 2026, 10:38 PM EDT
Completed Phase 3 Interventional Results available

Effects of Desoximetasone Spray 0.25% in Patients With Moderate to Severe Plaque Psoriasis

NCT01206660
View directory record Official record
Conditions
Psoriasis
Interventions
Desoximetasone Spray 0.25%, placebo
Drug
Lead sponsor
Sun Pharmaceutical Industries, Inc.
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Hazleton, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 2, 2014 · Synced Jul 21, 2026, 10:38 PM EDT
Completed Phase 3 Interventional Results available

Phase 3 Study of M923 and Humira® in Subjects With Chronic Plaque-type Psoriasis

NCT02581345
View directory record Official record
Conditions
Chronic Plaque Psoriasis, Psoriasis
Interventions
M923, Humira
Biological
Lead sponsor
Momenta Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
572 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
24
States / cities
Beverly Hills, California • Encino, California • La Mesa, California + 20 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2018 · Synced Jul 21, 2026, 10:38 PM EDT
Recruiting Phase 2 Interventional

Dose Ranging Study of ORKA-002 in Patients With Moderate-to-Severe Plaque Psoriasis

NCT07474792
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
ORKA-002, Placebo
Drug · Other
Lead sponsor
Oruka Therapeutics, Inc.
Industry
Eligibility
18 Years to 79 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
24
States / cities
Birmingham, Alabama • Fountain Valley, California • Los Angeles, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Jul 21, 2026, 10:38 PM EDT
Completed No phase listed Observational

Evaluation of the Effectiveness of Secukinumab in Patients With Moderate to Severe Plaque Psoriasis

NCT05344482
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
Secukinumab
Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
277 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 30, 2022 · Synced Jul 21, 2026, 10:38 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A First in Human Study to Evaluate Safety, Tolerability, and Pharmacology of PF-06826647 in Healthy Subjects and Subjects With Plaque Psoriasis

NCT03210961
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
PF-06826647 tablet, PF-06826647 oral suspension, Placebo oral solution/suspension, Placebo tablet
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
109 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated Mar 30, 2020 · Synced Jul 21, 2026, 10:38 PM EDT
Completed Phase 2 Interventional Results available

Apremilast Safety and PK Study in Recalcitrant Plaque Psoriasis

NCT00521339
View directory record Official record
Conditions
Psoriasis-Type Psoriasis, Plaque-Type Psoriasis
Interventions
Apremilast
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
4
States / cities
Boston, Massachusetts • St Louis, Missouri • Portland, Oregon + 1 more
Source: ClinicalTrials.gov public record
Updated May 6, 2020 · Synced Jul 21, 2026, 10:38 PM EDT
Completed Phase 3 Interventional Results available

Study of Safety, Tolerability, and Efficacy of Secukinumab in Subjects With Moderate to Severe Palmoplantar Psoriasis

NCT01806597
View directory record Official record
Conditions
Moderate to Severe Palmoplantar Psoriasis
Interventions
secukinumab 150 mg, secukinumab 300 mg, Placebo
Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
8
States / cities
Birmingham, Alabama • Phoenix, Arizona • Indianapolis, Indiana + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2018 · Synced Jul 21, 2026, 10:38 PM EDT
Completed Phase 2 Interventional Results available

The Safety, Efficacy and Pharmacokinetics of ARQ-151 Cream in Subjects With Chronic Plaque Psoriasis

NCT03638258
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
Roflumilast Cream 0.3%, Roflumilast Cream 0.15%, Vehicle Cream
Drug
Lead sponsor
Arcutis Biotherapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
331 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
20
States / cities
Beverly Hills, California • Northridge, California • San Diego, California + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2022 · Synced Jul 21, 2026, 10:38 PM EDT
Completed Phase 2 Interventional Results available

A Study to Assess the Efficacy, Safety, and Tolerability of KPL-716 in Reducing Pruritus in Chronic Pruritic Diseases

NCT03858634
View directory record Official record
Conditions
Chronic Idiopathic Urticaria, Chronic Idiopathic Pruritus, Lichen Planus, Lichen Simplex Chronicus, Plaque Psoriasis
Interventions
KPL-716, Placebo
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
14
States / cities
Anniston, Alabama • Phoenix, Arizona • Hot Springs, Arkansas + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2025 · Synced Jul 21, 2026, 10:38 PM EDT
Completed Phase 2 Interventional

A Safety Study of 188-0551 Spray Versus Reference Listed Drug (RLD) in Adult Subjects With Plaque Psoriasis

NCT04080206
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
188-0551 Spray, RLD
Drug
Lead sponsor
Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
3
States / cities
Scottsdale, Arizona • Thousand Oaks, California • Miami, Florida
Source: ClinicalTrials.gov public record
Updated May 9, 2021 · Synced Jul 21, 2026, 10:38 PM EDT
Completed Phase 1 Interventional Results available

A Study of Ixekizumab in Participants With Plaque Psoriasis

NCT02993471
View directory record Official record
Conditions
Psoriasis
Interventions
Drug Cocktail, Ixekizumab
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
3
States / cities
Anaheim, California • DeLand, Florida • High Point, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 11, 2019 · Synced Jul 21, 2026, 10:38 PM EDT
Completed Phase 3 Interventional Results available

A Study of the Efficacy and Safety of DFD-06 Cream in the Treatment of Moderate to Severe Plaque Psoriasis

NCT02635204
View directory record Official record
Conditions
Psoriasis
Interventions
DFD06 Cream, Vehicle Cream
Drug
Lead sponsor
Promius Pharma, LLC
Industry
Eligibility
18 Years and older
Enrollment
267 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
30
States / cities
Glendale, Arizona • Rogers, Arkansas • Fountain Valley, California + 26 more
Source: ClinicalTrials.gov public record
Updated May 14, 2018 · Synced Jul 21, 2026, 10:38 PM EDT
Completed Phase 3 Interventional Results available

Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis

NCT02826603
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
Secukinumab, Ustekinumab
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
1,114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
123
States / cities
Anniston, Alabama • Birmingham, Alabama • Mobile, Alabama + 103 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2019 · Synced Jul 21, 2026, 10:38 PM EDT
Completed Phase 2 Interventional Results available

High Dose Risankizumab for Psoriasis

NCT05283135
View directory record Official record
Conditions
Psoriasis
Interventions
risankizumab
Drug
Lead sponsor
Oregon Medical Research Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Oct 23, 2025 · Synced Jul 21, 2026, 10:38 PM EDT
Completed Phase 2 Interventional

Study to Assess VB-201 in Patients With Psoriasis

NCT01001468
View directory record Official record
Conditions
Active Plaque Psoriasis
Interventions
VB-201, Placebo
Drug · Other
Lead sponsor
Vascular Biogenics Ltd. operating as VBL Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
10
States / cities
Boston, Massachusetts • Haverhill (Boston), Massachusetts • St Louis, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 15, 2011 · Synced Jul 21, 2026, 10:38 PM EDT
Completed Not applicable Interventional Results available

Light Treatment Effectiveness (LITE) Study

NCT03726489
View directory record Official record
Conditions
Psoriasis, Psoriatic Plaque
Interventions
Daavlin 7 series 3 panel narrow band phototherapy home units, narrow band phototherapy clinic units
Device
Lead sponsor
University of Pennsylvania
Other
Eligibility
12 Years and older
Enrollment
783 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
38
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Fort Smith, Arkansas + 31 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Jul 21, 2026, 10:38 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Comparative Efficacy of CNTO 1959 (Guselkumab) and Secukinumab for the Treatment of Moderate to Severe Plaque-type Psoriasis

NCT03090100
View directory record Official record
Conditions
Psoriasis
Interventions
Guselkumab, Placebo, Secukinumab
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
1,048 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
44
States / cities
Birmingham, Alabama • Los Angeles, California • Oceanside, California + 38 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2019 · Synced Jul 21, 2026, 10:38 PM EDT
Completed Phase 1 Interventional

Evaluate Safety and Tolerability of Calcipotriene Foam 0.005% in Pediatric Subjects With Mild/Moderate Plaque Psoriasis

NCT01582932
View directory record Official record
Conditions
Psoriasis
Interventions
Calcipotriene 0.005% Foam
Drug
Lead sponsor
Mayne Pharma International Pty Ltd
Industry
Eligibility
2 Years to 11 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
36
States / cities
Birmingham, Alabama • Rogers, Arkansas • Encino, California + 30 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2019 · Synced Jul 21, 2026, 10:38 PM EDT
Completed Phase 2 Interventional Results available

A Phase 2b Study of Baricitinib in Participants With Moderate to Severe Psoriasis

NCT01490632
View directory record Official record
Conditions
Psoriasis, Skin Diseases, Skin Diseases, Papulosquamous
Interventions
Placebo, Baricitinib
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
271 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
18
States / cities
Bakersfield, California • Santa Monica, California • Miami, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 26, 2019 · Synced Jul 21, 2026, 10:38 PM EDT
Completed Phase 4 Interventional Results available

Long-Term One Year Use of Alefacept (Amevive®) in Moderate to Severe Chronic Plaque Type Psoriasis

NCT00655564
View directory record Official record
Conditions
Psoriasis
Interventions
Alefacept
Drug
Lead sponsor
Wake Forest University
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 10, 2018 · Synced Jul 21, 2026, 10:38 PM EDT